Brief: Sensorion: Positive DSMB Review, Continuation Of Phase 2 Clinical Trial For SENS-111

Sensorion SA

15/05/2019 06:50

May 15 (Reuters) - SENSORION SA  ALSEN.PA :
    * SENSORION ANNOUNCES THE POSITIVE DATA SAFETY MONITORING
BOARD
(DSMB) REVIEW AND CONTINUATION OF THE PHASE 2 CLINICAL TRIAL FOR
SENS-111 IN ACUTE UNILATERAL VESTIBULOPATHY (AUV)
    * 86 PATIENTS ENROLLED IN SENS-111 CLINICAL TRIAL
    * TRIAL RESULTS WILL BE AVAILABLE IN SECOND HALF OF 2019 IN
ORDER
TO ASSESS EFFICACY OF CANDIDATE DRUG
    * CONFIRMED THE ABSENCE OF ANY CONCERN AS TO THE SAFETY OF
SENS
111 AND  RECOMMENDED CONTINUING  TRIAL AS SCHEDULED AND
ENROLLING THE REMAINING PATIENTS
    * NUMBER OF EXPECTED PATIENTS IS SOME 100 IN CENTERS OPEN IN
US,
EUROPE, ISRAEL AND SOUTH KOREA.

Source text for Eikon:  ID:nBw7dF1YKa 
Further company coverage:  ALSEN.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))